Tech Company Financing Transactions
Ultragenyx Pharmaceutical Funding Round
Ultragenyx Pharmaceutical, based in Novato, raised $75 million in funding from Adage Capital Management, BlackRock and F-Prime Capital.
Transaction Overview
Company Name
Announced On
12/20/2012
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series B
Investors
Proceeds Purpose
The company will use the proceeds to advance development of its meaning clinical stage programs, UX001 and UX003, as well as other undisclosed programs.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
60 Leveroni Ct.
Novato, CA 94949
USA
Novato, CA 94949
USA
Phone
Website
Email Address
Overview
Ultragenyx (NASDAQ: RARE) is focused on developing therapeutics for rare diseases. The company will build on management's experience in choosing and developing products with clear mechanisms of action in untreated rare diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Emil Kakkis
Chief Financial Officer
Shalini Sharp
Chief Operating Officer
John Pinion
VP - Bus. Development
Thomas Kassberg
Browse more venture capital transactions:
Prev: 12/20/2012: bMobilized venture capital transaction
Next: 12/20/2012: Sightly venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs